Patents Assigned to Genzyme Corporation
  • Methods of culturing a mammalian cell
    Patent number: 11306341
    Abstract: Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 19, 2022
    Assignee: Genzyme Corporation
    Inventors: Christopher Hwang, Timothy Johnson, Jason Walther, Cheng Cheng, Jonathan Wang, Neha Shah, Seul-A Bae
  • TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS)
    Publication number: 20220110922
    Abstract: This disclosure relates to a method of treating a ciliopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said method.
    Type: Application
    Filed: February 4, 2020
    Publication date: April 14, 2022
    Applicant: GENZYME CORPORATION
    Inventors: Oxana IBRAGHIMOV-BESKROVNAYA, Nikolay O. BUKANOV, Hervé HUSSON, Sarah E. MORENO
  • Use of iNOS inhibitors to increase viral yield in culture
    Patent number: 11299715
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 12, 2022
    Assignee: Genzyme Corporation
    Inventors: Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
  • Oligosaccharide-protein conjugates
    Patent number: 11279725
    Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: March 22, 2022
    Assignee: Genzyme Corporation
    Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
  • SERPINC1 iRNA Compositions and Methods of Use Thereof
    Publication number: 20220079971
    Abstract: The invention relates to pharmaceutical compositions comprising an iRNA agent, e.g., double stranded ribonucleic acid (dsRNA) agent and methods of using such compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).
    Type: Application
    Filed: January 16, 2020
    Publication date: March 17, 2022
    Applicant: Genzyme Corporation
    Inventor: Akin Akinc
  • Integrated Continuous Isolation of Fluid Streams From Sterile Process Vessels
    Publication number: 20220081669
    Abstract: Provided herein are isolation processes and the associated hardware to allow fluid streams to be isolated from a sterilized system (e.g., a sterile process vessel) that contains a sterile process. The isolation processes described herein allow for continuous removal of fluid streams (e.g., waste streams, liquid containing recombinant therapeutic proteins) from a sterilized system (e.g., a biological manufacturing system), which provides for less manual manipulation of the sterilized system and a decreased risk of contaminating the sterilized system.
    Type: Application
    Filed: November 24, 2021
    Publication date: March 17, 2022
    Applicant: Genzyme Corporation
    Inventor: Robert Snow
  • Colony stimulating factor-1 receptor (CSF-1R) inhibitors
    Patent number: 11274108
    Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: March 15, 2022
    Assignee: GENZYME CORPORATION
    Inventors: John L. Kane, Jr., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Wai-Kwok Shum, Linli Wei
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20220073508
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
    Type: Application
    Filed: April 14, 2021
    Publication date: March 10, 2022
    Applicant: Genzyme Corporation
    Inventors: Elyse BOURQUE, Mario A. CABRERA-SALAZAR, Cassandra CELATKA, Seng H. CHENG, Bradford HIRTH, Andrew GOOD, Katherine JANCSICS, John MARSHALL, Markus METZ, Ronald K. SCHEULE, Renato SKERLJ, Yibin XIANG, Zhong ZHAO, John LEONARD, Thomas NATOLI, Elina MAKINO, Herve HUSSON, Oxana BESKROVNAYA
  • Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
    Patent number: 11267924
    Abstract: Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: March 8, 2022
    Assignee: GENZYME CORPORATION
    Inventors: Pradeep K. Dhal, Robert J. Miller, Steven C. Polomoscanik, Philip Just Larsen, Thomas Huebschle, Thorsten Schmidt, Ian Davison, Peter D. McDonnell, Chinyere Agbugba
  • FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOF
    Publication number: 20220064262
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: July 2, 2021
    Publication date: March 3, 2022
    Applicants: Genzyme Corporation, Genzyme Corporation
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
    Patent number: 11261463
    Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: March 1, 2022
    Assignee: Genzyme Corporation
    Inventors: Guang Qu, John Fraser Wright
  • Slow intraventricular delivery
    Patent number: 11253485
    Abstract: Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier. Similarly, diagnostic agents and anesthetic agents can be delivered to the brain in this manner. The administration can be performed slowly to achieve maximum effect. Such administration permits greater penetration of distal portions of the brain.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: February 22, 2022
    Assignee: Genzyme Corporation
    Inventors: James C. Dodge, Marco A. Passini, Lamya S. Shihabuddin, Seng H. Cheng
  • Humanized anti-complement factor Bb antibodies
    Patent number: 11242382
    Abstract: Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: February 8, 2022
    Assignee: Genzyme Corporation
    Inventors: Graham Parry, Stephen Moore, Michael Storek, Nina C. Leksa
  • Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
    Publication number: 20220033377
    Abstract: The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof. The invention also relates to processes for the manufacture of certain intermediates useful in the manufacture of the quinazoline derivatives and to processes for the manufacture of the quinazoline derivatives utilising said intermediates. In particular, the present invention relates to chemical processes and intermediates useful in the manufacture of the compound 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline.
    Type: Application
    Filed: November 2, 2020
    Publication date: February 3, 2022
    Applicant: Genzyme Corporation
    Inventors: Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
  • Methods for enhanced removal of impurities during protein A chromatography
    Patent number: 11236126
    Abstract: Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and/or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: February 1, 2022
    Assignee: GENZYME CORPORATION
    Inventor: Carl A. Beigie
  • METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES
    Publication number: 20220023273
    Abstract: This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with lysosomal storage diseases using quinuclidine compounds of formula (I), optionally in combination with enzyme replacement therapy. This includes pain, such as abdominal pain, and dermatological disorders, such as angiokeratoma, in a patient having a disease such as Fabry disease. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods.
    Type: Application
    Filed: February 3, 2020
    Publication date: January 27, 2022
    Applicant: GENZYME CORPORATION
    Inventors: Nigel Patrick Somerville CRAWFORD, Tanya Zaremba FISCHER
  • Methods for treating osteogenesis imperfecta
    Patent number: 11230595
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: January 25, 2022
    Assignees: Genzyme Corporation, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES
    Publication number: 20220016092
    Abstract: This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with lysosomal storage diseases using quinuclidine compounds of formula (I), optionally in combination with enzyme replacement therapy. This includes supranuclear gaze palsies, including horizontal and vertical saccadic gaze palsies, and cognitive deficits or gait disorders, such as in a patient having Gaucher disease or Niemann-Pick disease Type C. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods.
    Type: Application
    Filed: February 3, 2020
    Publication date: January 20, 2022
    Applicant: GENZYME CORPORATION
    Inventors: Nigel Patrick Somerville CRAWFORD, Tanya Zaremba FISCHER
  • METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER
    Publication number: 20220017902
    Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 20, 2022
    Applicant: Genzyme Corporation
    Inventors: Akin Akinc, Benny Sorensen, Pushkal Garg, Gabriel Robbie
  • Anti-Human CD52 Immunoglobulins
    Publication number: 20220010024
    Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.
    Type: Application
    Filed: March 3, 2021
    Publication date: January 13, 2022
    Applicant: Genzyme Corporation
    Inventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders